How to Get Zepbound Online (Tirzepatide) in 2026
Zepbound is Eli Lilly's tirzepatide injection, FDA-approved in November 2023 for chronic weight management and the only dual GIP + GLP-1 receptor agonist with an obesity indication. The SURMOUNT-1 trial (NEJM 2022) reported -22.5% mean body weight loss at 72 weeks on the 15 mg dose, the largest weight-loss figure ever recorded in a phase 3 obesity trial. Eli Lilly's LillyDirect cash-pay launched in 2024 with vials priced at **$349–$549/mo** depending on dose, undercutting the standard pen at retail (~$1,200/mo). Below: which telehealth providers offer Zepbound, vial vs pen pricing, and how to navigate the LillyDirect channel through telehealth.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Zepbound contains tirzepatide, a once-weekly subcutaneous injection that activates both GIP and GLP-1 receptors, mechanistically distinct from semaglutide which targets GLP-1 alone. FDA-approved November 2023 for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. In 2024 the label was expanded to cover obstructive sleep apnea in adults with obesity (SURMOUNT-OSA trial). Available as auto-injector pens (5 dose strengths: 2.5, 5, 7.5, 10, 12.5, 15 mg) and as single-dose vials through LillyDirect at lower cash-pay rates.
Adults with BMI ≥30, or BMI ≥27 with hypertension, type 2 diabetes, dyslipidaemia, or OSA. Particularly strong fit for patients who have plateaued on semaglutide and want the additional weight-loss potential of dual-receptor agonism, or for patients with comorbid OSA who can leverage the dual indication. Same MTC/MEN-2 contraindications as Wegovy. Patients with severe gastroparesis or active pancreatitis should be evaluated carefully.
Standard 16-week titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, escalating every 4 weeks if tolerated. Most patients can stop at the 10 mg or 12.5 mg dose if they hit goal weight. **LillyDirect cash-pay vials are $349/mo (5 mg) and $549/mo (7.5 mg+)** for self-pay patients, currently the cheapest legitimate route. Pen format runs $1,000–$1,300/mo at retail without insurance, dropping to $400–$700/mo with the Lilly savings card on commercial plans. Through telehealth all-in expect $400–$900/mo depending on whether the platform sources from LillyDirect vials or retail pens. Side-effect profile similar to Wegovy: nausea (29%), diarrhoea (23%), constipation (17%) per SURMOUNT-1.
Verified Offers for Zepbound
Zepbound vs. Wegovy: How Tirzepatide's Dual Mechanism Changes the Math
Zepbound (tirzepatide) activates two receptors. GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), while Wegovy (semaglutide) targets GLP-1 alone. The dual mechanism appears to produce greater weight loss in head-to-head data: the SURMOUNT-5 trial (2024) found tirzepatide 10–15 mg produced 20.2% mean body weight loss versus 13.7% for semaglutide 2.4 mg at 72 weeks, a meaningful difference in absolute terms, roughly 15 lbs more lost on tirzepatide for a 200 lb patient. See also the SURMOUNT-1 primary publication (NEJM 2022) for the full efficacy and safety data.
The GIP receptor activation is thought to improve the tolerability profile: SURMOUNT-1 (NEJM 2022) reported lower rates of nausea (29%) and vomiting (12%) compared to Wegovy's STEP 1 data (NEJM 2021) (44% nausea, 25% vomiting). This makes Zepbound a particularly strong option for patients who tried semaglutide and discontinued due to GI side effects.
Cost is the main counterargument. LillyDirect vials are $349–$549/month, and most telehealth platforms price all-in at $400–$900/month. higher than the NovoCare Wegovy cash-pay floor of $499/month for all dose tiers. The decision rule: if you have no insurance coverage and cost is the primary constraint, Wegovy via NovoCare is cheaper. If you have commercial insurance that covers both, or if you previously discontinued semaglutide due to GI side effects, Zepbound is the stronger clinical choice.
LillyDirect Cash-Pay: What It Is and How to Access It Through Telehealth
LillyDirect is Eli Lilly's direct-to-patient pharmacy program, launched in 2024 to offer Zepbound single-dose vials at a lower cash-pay price than retail pens. The vials are priced at $349/month for the 2.5 and 5 mg doses, and $549/month for 7.5 mg and above. To access LillyDirect pricing, you need a valid Zepbound prescription from a licensed US clinician, which is where telehealth platforms come in.
Most telehealth platforms that offer Zepbound can route your prescription to LillyDirect. The practical workflow: complete your telehealth intake and receive a prescription, then either the platform routes it to LillyDirect directly, or you take the prescription to LillyDirect.com yourself. FuturHealth, TMates, and TrimRx all have documented LillyDirect routing workflows. Note that vials require self-injection with a separate syringe. if you prefer the auto-injector pen format, you'll pay retail pricing (~$1,000–$1,300/month without insurance).
The LillyDirect savings card is separate from the vial program: it's for the pen format on commercial insurance and can reduce copays to as low as $25/month for covered patients. The savings card cannot be used with Medicare, Medicaid, or other government programs. If you have commercial insurance, the savings card route is almost always cheaper than cash-pay vials.
What the Studies Actually Show
Zepbound is FDA-approved tirzepatide for chronic weight management. The evidence below comes from the SURMOUNT trials (which led to the 2023 obesity approval) and the SURMOUNT-OSA trial (which led to the 2024 OSA-in-obesity approval).
| Endpoint | Finding |
|---|---|
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)1 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)2 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)3 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
| GI side effects (FDA prescribing information)4 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥5%, constipation ≥5% |
| Boxed warning4 | Risk of thyroid C-cell tumors observed in rodent studies; contraindicated in personal/family history of MTC or MEN 2 |
| A1C reduction (T2D, SURPASS program)5 | ≈1.9–2.4% A1C reduction at 15 mg weekly across SURPASS-1 through SURPASS-5 |
| Compounded tirzepatide — evidence basis6 | Active ingredient is identical to Zepbound/Mounjaro; efficacy is inferred from the active ingredient. FDA does not formally approve compounded products |
Frequently Asked Questions
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- FDA Prescribing Information — Zepbound (tirzepatide) · ZEPBOUND (tirzepatide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.